Myasthenia gravis with anti-muscle-specific tyrosine kinase antibodies during therapy for multiple myeloma: a case report
Open Access
- 12 June 2020
- journal article
- research article
- Published by Springer Science and Business Media LLC in BMC Neurology
- Vol. 20 (1), 1-4
- https://doi.org/10.1186/s12883-020-01813-1
Abstract
The onset of myasthenia (MG) gravis with anti-muscle-specific tyrosine kinase (MuSK) antibodies most commonly peaks in the fourth decade of life, and MG with MuSK antibodies (MuSK-MG) rarely coexists with a malignant tumor. To date, MuSK-MG has not been reported in multiple myeloma (MM). A 60-year-old male with MM who was receiving treatment with bortezomib and thalidomide presented diplopia, ptosis, and limb weakness. A diagnosis of MM with Bence-Jones proteinuria was established when he was 56 years old, and he received chemotherapy with four courses of bortezomib and dexamethasone. Although he received thalidomide as maintenance therapy, it was discontinued a year before hospital admission because of sensory neuropathy as a side effect. Six months before hospital admission, he developed mild diplopia. One month before admission, his chemotherapy was interrupted because of viral infection and fatigability. Then he developed neck weakness and bilateral ptosis. A diagnosis of MuSK-MG was made based on neurological and serological examinations. According to the previous relevant literature, this is the first report of MuSK-MG in a patient with MM. In patients with MM, the possibility of co-existing of autoimmune disease, including MuSK-MG, should be considered. This case emphasizes the need to still consider testing for anti-MuSK antibodies in older MM patients where there is clinical suspicion for possible MG despite negative anti-acetylcholine receptor antibodies and lacking classic MuSK MG phenotype at onset.Funding Information
- Japan Society for the Promotion of Science (18K15446)
This publication has 21 references indexed in Scilit:
- Proteasome Inhibition with Bortezomib Depletes Plasma Cells and Specific Autoantibody Production in Primary Thymic Cell Cultures from Early-Onset Myasthenia Gravis PatientsThe Journal of Immunology, 2014
- Diplopia and Variable Ptosis as the Sole Initial Findings in a Case of Orbital Plasmacytoma and Multiple MyelomaSeminars in Ophthalmology, 2013
- Targeting plasma cells with proteasome inhibitors: possible roles in treating myasthenia gravis?Annals of the New York Academy of Sciences, 2012
- Anti‐musk antibody myasthenia gravis: Clinical findings and response to treatment in two large cohortsMuscle & Nerve, 2011
- Clinical and experimental features of MuSK antibody positive MG in JapanEuropean Journal of Neurology, 2007
- Clinical predictors of steroid-induced exacerbation in myasthenia gravisJournal of Clinical Neuroscience, 2006
- Multiple Myeloma in a Patient with Systemic Lupus Erythematosus, Myasthenia Gravis and Non-Familial Diffuse Palmoplantar KeratodermaLeukemia & Lymphoma, 2004
- Generating Hypotheses by Discovering Implicit Associations in the Literature: A Case Report of a Search for New Potential Therapeutic Uses for ThalidomideJournal of the American Medical Informatics Association, 2003
- Myasthenia gravisNeurology, 2000
- Myasthenia gravis with a myeloma-type, gamma-G (IgG) immunoglobulin abnormalityThe American Journal of Medicine, 1969